Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Sutro Biopharma Inc
STRO
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$10.94
-0.52
-4.54%
Dern. MÀJ: Oct 16, 4:27 PM
$10.94
-0.52
-4.54%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Sutro Biopharma Financials
Sutro Biopharma (STRO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dose and the next update planned for 2027.
Vandana Singh
PRO
Sutro Biopharma Q2 EPS $(2.33) Misses $(2.19) Estimate, Sales $9.839M Miss $13.048M Estimate
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.33) per share which missed the analyst consensus estimate of $(2.19) by 6.39 percent. This is a 66.43 percent decrease over losses of $(1.40) per share from
Benzinga Newsdesk
PRO
Sutro Biopharma Q1 EPS $(2.94) Beats $(3.77) Estimate, Sales $14.523M Beat $8.079M Estimate
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.94) per share which beat the analyst consensus estimate of $(3.77) by 22.02 percent. This is a 67.69 percent increase over losses of $(9.10) per share from
Benzinga Newsdesk
PRO
Sutro Biopharma Q4 EPS $(5.29) Misses $(4.35) Estimate, Sales $11.647M Beat $8.341M Estimate
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(5.29) per share which missed the analyst consensus estimate of $(4.35) by 21.58 percent. This is a 40.56 percent increase over losses of $(8.90) per share from
Benzinga Newsdesk
PRO
Sutro Biopharma Q3 EPS $(0.67) Misses $(0.41) Estimate, Sales $9.693M Beat $9.132M Estimate
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.41) by 65.02 percent. This is a 13.56 percent decrease over losses of $(0.59) per share from
Benzinga Newsdesk
PRO
Sutro Biopharma To Continue To Reorganize Restructuring And Related Costs For Deprioritzation Of Luvelta Program; Expected To Recognize Portion In 2025
Benzinga Newsdesk
